Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Imaging and Biology"
DOI: 10.1007/s11307-020-01518-4
Abstract: Radioimmunotherapy uses tumor-specific antibodies to deliver therapeutic radionuclides, but hematological toxicity due to the long serum half-life of intact antibodies remains a challenge. We evaluated a smaller antibody fragment, the minibody, with faster kinetics and… read more here.
Keywords: a11; dtpa a11; minibody; 177lu dtpa ... See more keywords
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-17-0554
Abstract: Anti-CD20 radioimmunotherapy is an effective approach for therapy of relapsed or refractory CD20pos lymphomas, but faces limitations due to poor tumor penetration and undesirable pharmacokinetics of full antibodies. Camelid single-domain Ab fragments (sdAb) might circumvent… read more here.
Keywords: sdab 9079; sdab; anti cd20; therapy ... See more keywords
CD123-targeted radiotheranostics of Acute Myeloid Leukemia with 89Zr/177Lu-labeled pivekimab
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5052
Abstract: Introduction CD123, the interleukin-3 receptor alpha chain, is highly-expressed on AML blasts and stem cells but less on normal counterparts, making it an attractive target for targeted therapy. Pivekimab sunirine (IMGN632) is an antibody–drug conjugate… read more here.
Keywords: dfo pive; 177lu dtpa; 89zr dfo; cd123 ... See more keywords